News - PharmaTher Holdings Ltd. Ketamine

OTCQB: PHRRF | CSE: PHRM

HOME
COMPANY
PIPELINE
INVESTORS
NEWS
CONTACT

HOME
COMPANY
PIPELINE
INVESTORS
NEWS
CONTACT

News

9/29/2021

PharmaTher Retains Former FDA Psychiatry Division Director Dr. Thomas Laughren as Regulatory Affairs Advisor

9/28/2021

PharmaTher Announces Closing of CAD$10 Million Private Placement with Institutional Investors

9/24/2021

PHARMATHER ANNOUNCES CAD$10 MILLION PRIVATE PLACEMENT WITH INSTITUTIONAL INVESTORS

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES
OR FOR DISSEMINATION IN THE UNITED STATE

9/21/2021

PharmaTher Added to the North American Psychedelics Index and First Psychedelic Exchange Traded Fund

9/13/2021

PharmaTher Provides Product Pipeline Updates and Anticipated Milestones for Q4-2021 and 2022

9/9/2021

PharmaTher to Present at H.C. Wainwright 23rd Annual Global Investment Conference

9/7/2021

PharmaTher Provides Business Highlights and Releases Annual Financials for Fiscal Year Ended May 31, 2021

Archives

February 2023
January 2023
December 2022
November 2022
October 2022
September 2022
July 2022
June 2022
May 2022
April 2022
March 2022
February 2022
January 2022
December 2021
November 2021
October 2021
September 2021
August 2021
July 2021
June 2021
May 2021
April 2021
March 2021
February 2021
January 2021
December 2020
November 2020
October 2020

Categories

COMPANY / RESEARCH / INVESTORS / NEWS / CONTACT

Publicly-traded on the OTCQB: PHRRF and CSE: PHRM

© COPYRIGHT 2023. PharmaTher Holdings Ltd. ALL RIGHTS RESERVED.